Novo Nordisk's Experimental Obesity Drug Shows Significant Weight Loss in Women
Novo Nordisk has released new data showing its experimental CagriSema injection achieved an average weight loss of 25% among adult women after 68 weeks, based on a post-trial analysis. The drug combines semaglutide with cagrilintide and is designed to target both GLP-1 and amylin pathways for enhanced obesity treatment. A second analysis showed consistent results across different menopause stages in over 1,900 women. CagriSema outperformed placebo significantly, which saw only about a 3% weight loss on average. The drug also demonstrated reductions in abdominal fat as measured by waist circumference for all groups studied. These findings build upon earlier Phase 3 trial results showing an overall average of 22.7% weight loss compared to 2.3% with placebo. Despite these promising outcomes, Wall Street has shown limited enthusiasm due to previous underwhelming late-stage data from CagriSema trials. However, Novo remains confident in the drug's potential and plans for its launch early next year.
Topics: CagriSema GLP-1 drugs obesity drug weight loss trial results
Part of the story Novo Nordisk's CagriSema Shows 25% Weight Loss in Phase 3 Clinical Trial (3 articles)